A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).

Trial Details

NCT ID
NCT06768489
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • JNJ-79635322
  • Daratumumab
  • Pomalidomide
  • Lenalidomide
Locations (sample)
  • Clayton, Australia|-37.91667,145.11667
  • Fitzroy, Australia|-37.79839,144.97833
  • Melbourne, Australia|-37.814,144.96332
  • Waratah, Australia|-32.90667,151.72647
  • Wollongong, Australia|-34.424,150.89345

Key Eligibility Criteria

  • Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria
  • Meet treatment regimen-specific requirements as follows: Treatment regimen A (JNJ-79635322+daratumumab):Treatment regimen A1: Have been treated wit…
  • Have a weight \>=40 kilograms
  • Must have an Eastern Cooperative Oncology Group status of 0 or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →